Coronavirus (COVID-19)
Learn more
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. Secondary purposes of the study are:
Eligibility Criteria:
This study is for patients age 18 and older.
Available at: Hospital of Central Connecticut
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.